EE68 Cost-Effectiveness of Second-Line Treatment for Advanced Endometrial Carcinoma in Taiwan: Lenvatinib Plus Pembrolizumab Versus Doxorubicin
Abstract
Authors
S.T. Chiang C.H. Chueh P.K. Ho Y.W. Wen Shiu M.N. J.H. Liu W.H. Li Y.W. Tsai